Shire ADR Reptg 3 Ord Shs: All Recent News

• All recent news
• Earnings news

Shire applies for Euro approval of Gaucher drug 8:50 AM

BOSTON (MarketWatch) -- Shire plc said early Tuesday that it has applied for European marketing approval of its drug velaglucerase alfa, a treatment for the rare genetic disorder Gaucher disease. The product is also awaiting approval in the U.S. If approved, the drug would compete against Genzyme Corp.'s flagship product Cerezyme. A third company, Israel's Protalix BioTherapeutics is also finishing development on a drug to treat the disorder. At MarketWatch

Shire Submits European Marketing Authorization Application... 7:06 AM

Committee for Medicinal Products for Human Use (CHMP) Grants Accelerated AssessmentDUBLIN, November 24 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty... PR Newswire

This Stock Is a Train Wreck 11/19/2009

Genzyme's string of missteps has investors nervous. At Motley Fool

Zacks Bull and Bear of the Day Highlights: Sealed Air... 11/17/2009

Zacks Equity Research highlights Sealed Air Corporation (NYSE: SEE) as the Bull of the Day and Hologic, Inc. (Nasdaq: HOLX) the Bear of the Day. In addition, Zacks Equity Research provides analysis... Business Wire

Genzyme's Termeer: Worst Biotech CEO of '09 11/17/2009

Genzyme CEO Henri Termeer is Adam Feuerstein's Worst Biotech CEO of the Year for 2009. At TheStreet.com

Shire Announces Publication of Open-Label Study on... 11/16/2009

Primary objective of the study was to evaluate the safety of coadministration of INTUNIV with stimulantsPHILADELPHIA, Nov. 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global... PR Newswire

Shire downgraded to hold at Lazard 11/16/2009

LONDON (MarketWatch) -- Analysts at Lazard Capital Markets downgraded drugmaker Shire to hold from buy on Monday, citing valuation. "We believe the stock's recent appreciation, especially in response to Friday's announcement of further manufacturing problems for Genzyme, positions the stock for little upside on a fundamental basis," the broker said. Positive catalysts are now reflected in the valuation, it said. At MarketWatch

Market Report -- In Play (SHPGY) 11/13/2009

Shire Plc breaks to fresh highs on a surge in volume as it climbs over 2 pts during the past 5 mins &nbsp... Briefing.com

Market Report -- In Play (SHPGY) 11/12/2009

Shire Plc announced findings that Vyvanse demonstrated significant improvement in ADHD symptoms Co announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with... Briefing.com

Shire Reports Findings From an Analysis Examining Emotional... 11/12/2009

Post hoc analysis of Phase 3 study data presented at national psychiatric meetingPHILADELPHIA, Nov. 12 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty... PR Newswire

Shire Re-Launches FOCUS, an Online, Personalized Patient... 11/11/2009

FOCUS program offers customized tips, tools, and practical strategies for adults with ADHD taking Vyvanse designed to help them manage their day-to-day lifePHILADELPHIA, Nov. 11... PR Newswire

Market Report -- In Play (SHPGY) 11/9/2009

Shire Plc announced the availability of INTUNIV Extended Release Tablets Co announced the availability of INTUNIV Extended Release Tablets in pharmacies across the United States for the treatment of... Briefing.com

Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets... 11/9/2009

In clinical studies, INTUNIV, a nonscheduled treatment for ADHD, demonstrated significant improvement in reducing ADHD symptoms which can be disruptive at home and at schoolPHILADELPHIA, Nov. 9... PR Newswire

Shire Extends Agreement with Medidata Solutions for Trial... 11/4/2009

Medidata Solutions (NASDAQ: MDSO), a leading global provider of hosted clinical development solutions, today announced a multi-year contract extension with Shire plc (LSE: SHP, NASDAQ: SHPGY) for use... Business Wire

FDA Grants Priority Review for Shire's velaglucerase alfa for... 11/4/2009

FDA Issued Action Date of February 28, 2010 Under the Prescription Drug User Free Act (PDUFA)CAMBRIDGE, Massachusetts, November 4 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the... PR Newswire

More News

Market Report

News by Symbol

Today's Investing Articles

Breaking News

News by Topic

News by Industry

MSNBC News

MSN Money

Search MSN Money

Message Boards

Site Status